Reviva Pharmaceuticals Announces Positive Results in Phase 3 Trial for Brilaroxazine
Reviva Pharmaceuticals Holdings announced today the successful completion of its pivotal Phase 3 trial evaluating the efficacy, safety, and tolerability of brilaroxazine in treating schizophrenia in adults. The trial yielded…